- Cara Therapeutics (NASDAQ:CARA) is up 13% premarket on robust volume in response to its announcement of positive results from a Phase 1 clinical trial assessing the safety and pharmacokinetics of oral CR845 in chronic kidney disease (CKD) patients undergoing hemodialysis.
- All four tablet strengths (0.25 mg, 0.5 mg, 1.0 mg, 2.5 mg) were generally well-tolerated when administered daily or three times per week after dialysis.
- On the pharmacokinetics front, plasma levels of orally administered CR845 were on par with clinically effective doses IV CR845 for the treatment of moderate-to-severe CKD-associated pruritis in hemodialysis patients.
- The company intends to assess oral CR845 in a non-dialysis CKD-associated pruritis population later this year.
- CR845, a peripherally acting kappa opioid receptor agonist, is being developed for the treatment of acute and chronic pain. Its value proposition is opioid-like analgesia without the respiratory depression or intestinal tract inhibition (constipation).
- Previously: Cara Therapeutics oral tablet version of pain candidate CR845 shows mixed results in mid-stage study; shares down 22% after hours (June 29)
Original article